A Hidden Cancer Risk in APS-1: What a New Scoping Review Found About Head and Neck Malignancies
Autoimmune Polyendocrine Syndrome Type 1, also called APS-1 or APECED, is a rare genetic disorder caused by mutations in both copies of the AIRE gene. AIRE plays a foundational role in immune education: it helps developing immune cells learn to recognize the body's own tissues as safe and leave them alone. When AIRE is missing or damaged, that learning process breaks down, and the immune system begins attacking multiple organs at once. The classic triad of APS-1 involves chronic mucocutaneous candidiasis (recurring fungal infections of the skin and mucous membranes), hypoparathyroidism (low parathyroid hormone, which disrupts calcium balance), and adrenal insufficiency (the adrenal glands failing to produce essential hormones like cortisol). Living with all three of these simultaneously is already enormously demanding.
A scoping review published in September 2025 in the International Journal of Molecular Sciences brings attention to a less widely recognized but serious additional hazard for people with APS-1: an elevated risk of squamous cell carcinoma (SCC) in the head, neck, and esophagus. Researchers searched PubMed, Scopus, and Web of Science for all published cases of APS-1 with histologically confirmed cancer in these regions, ultimately analyzing nine publications describing 19 patients and 26 tumors combined.
The pattern that emerged is striking. Tumors occurred most frequently in the oral cavity, accounting for 65% of cases, followed by the lip at 19% and the esophagus at 15%. In 96% of cases, the tumor type was squamous cell carcinoma. The mean age at cancer diagnosis was 35 years, with approximately 24 years having elapsed between the initial APS-1 diagnosis and the cancer diagnosis. This long latency suggests that the disordered immune environment of APS-1 gradually creates conditions in which cancer can develop, rather than causing an immediate or obvious risk.
One of the most important findings is that many of these patients lacked the usual cancer risk factors. A large proportion did not smoke or drink alcohol, meaning the malignancies did not arise from classic lifestyle behaviors but from the biology of the disease itself. Researchers suspect that the chronic mucosal candidiasis so common in APS-1 plays a direct role: persistent fungal infection inflames and damages the lining of the mouth and esophagus over time, potentially triggering malignant transformation. Disordered immune surveillance, another hallmark of APS-1, may also allow early cancer cells to escape detection.
The treatment picture is serious. Most patients required surgery, frequently combined with radiotherapy or chemoradiotherapy, alongside long-term antifungal therapy. Despite these intensive treatments, the overall survival rate was only approximately 50%. Recurrence occurred in 38% of patients, and 26% went on to develop a second primary tumor. Pooled cohort data suggest that roughly 10% of people with APS-1 may develop a head or neck malignancy over their lifetime, though the true lifetime figure remains uncertain given the rarity of the condition.
The authors make a clear recommendation: lifelong cancer surveillance should become a routine component of APS-1 management, ideally delivered through multidisciplinary care teams that include immunologists, oncologists, gastroenterologists, and oral medicine specialists. They also emphasize the importance of antifungal stewardship, since controlling mucosal candidiasis may reduce one of the key drivers of cancer risk. For patients and families managing APS-1, this review is a prompt to discuss cancer screening with your specialist team and ensure that regular monitoring of the mouth, throat, and esophagus is built into your ongoing care plan.